A Study of Ivonescimab in First-Line ES-SCLC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of Ivonescimab in First-Line ES-SCLC — Stella

Recruiting

Back to Extensive-stage Small Cell Lung Cancer (ES-SCLC) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

China

Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing Municipality

The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi

Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai, Shanghai Municipality

Key details

Phase

Safety & dosing

Sponsor

Akeso

Enrollment target

~180 participants

Started

October 2025

Primary completion

December 2027

Age range

18 Years – 75 Years

Last updated November 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov